Our research laboratory is currently pursuing two major projects:
A.
The biology of HDAC1 (and HDAC2) and how its post-translational modifications cross-talk and control its activity, also in light of its potential significance as a target for cancer therapy.
B.
The regulation and exploitation of the SUMO (Small Ubiquitin-like-Modifier) pathway by oncoviral proteins.